IgG anti-tTG responses in different autoimmune conditions differ in their epitope targets and subclass usage

Comerford, Ross; Kelly, Jacinta; Feighery, Conleth; Byrne, Greg

doi:10.1016/j.molimm.2015.06.026

Cited by 10 publications

(8 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies analyzing IgG subclasses are quite scarce. Comerford [15] analyzed IgG-TTG by age and showed that IgG-TTG levels were highest in celiac children 0-4 years of age (which coincides with Agardth study [39]) and significantly higher compared to that of CD patients aged 4-8 years (p= 0.0225), and adults celiacs (p= 0.0009); IgG2 was present in 35% of patients, IgG3 was greater in adults than in children and IgG4 was higher among children. Distribution of IgG subclasses was similar in diabetic patients but different from patients with Crohn's disease, where IgG3 and IgG4 predominated (69%), while in granulomatosis with polyangiitis IgG1 was always negative and positivity was given by IgG2 and IgG3.…”

Section: Ttg Igg-ttg and Antibodies Subclassessupporting

confidence: 63%

“…Both have high sensitivity and specificity, over 90% in children and adults [11]. Sensitivity and specificity are lower for measurements of IgG-TTG; Comerford et al described IgG-TTG positivity was 22% among pediatric patients and 47% in adults [15]. Despite these figures, it is interesting that IgG-TTG values were always higher in patients with untreated CD and both in children and adults results were higher in patients than in controls.…”

Section: Ttg and Elisa Kitsmentioning

confidence: 98%

“…In CD the predominant subclass is IgG1 [38]. This subclass is also found in DMT1, but it is infrequent in Crohn's disease and in granulomatosis with polyangiitis [15]. Studies analyzing IgG subclasses are quite scarce.…”

Section: Ttg Igg-ttg and Antibodies Subclassesmentioning

confidence: 99%

See 2 more Smart Citations

IgA and IgG Antitransglutaminase 2 Antibodies in the Diagnosis of Celiac Disease

Villanueva¹,

Rojas²,

Araya³

2017

IJCD

View full text Add to dashboard Cite

Screening for celiac disease (CD) dramatically improved when techniques able to measure blood autoantibodies against tissue transglutaminase 2 (TTG) were developed. Although typically increased in CD, these antibodies are not pathognomonic since they are also detected in several other autoimmune processes. IgA deficiency among celiac patients is more frequent than in general population (up to 25% vs 1-3%). This led to develop kits able to measure IgG-TTG, which until today represent a helpful diagnostic tool during diagnosis of CD in IgA deficient individuals. Today, commercial kits measuring IgG-TTG (and other) antibodies are widely available, are frequently used and create confusion in diagnosing CD in IgA-sufficient individuals. This is attributed to the fact that sensitivity and specificity of IgG-TTG is lower when applied to IgA-sufficient persons, and also because IgG-TTG is detected in several autoimmune disorders, with variable frequency and isotypes depending on the condition. Evidence analyzed indicate that to date available data: i) is insufficient to understand the difference of classes and subclasses detected in CD and other autoimmune conditions; ii) does not support the use of IgG-TTG for diagnosing CD in IgA-sufficient individuals and therefore iii) IgG should not be used in the routine diagnostic process of CD.

show abstract

Section: Ttg Igg-ttg and Antibodies Subclassessupporting

confidence: 63%

Section: Ttg and Elisa Kitsmentioning

confidence: 98%

See 1 more Smart Citation

IgA and IgG Antitransglutaminase 2 Antibodies in the Diagnosis of Celiac Disease

Villanueva¹,

Rojas²,

Araya³

2017

IJCD

View full text Add to dashboard Cite

show abstract

“…Low levels of anti-tTG Ab have been described in several disorders unrelated to CD, such as other autoimmune diseases, infections, tumors, myocardial damage, liver disorders, and psoriasis [18,19].…”

Section: Resultsmentioning

confidence: 99%

Chemiluminescent Immunoassay versus Enzyme Linked Immunosorbent Assays for IgA Anti-Tissue Transglutaminase Antibodies Assessment in Celiac Disease Children

Belei¹,

Iacob²,

Iacob³

et al. 2020

Rev. Chim.

View full text Add to dashboard Cite

Recent describing of atypical, silent and latent form of celiac disease (CD) increased the preocupation for screening methods.To perform a comparative study of immunoglobulin A (IgA) anti tissue-transglutaminase (tTG) antibodies (Ab) assessment using chemiluminescence versus Enzyme Linked Immunosorbent Assay (ELISA).The study included two lots.The first lot consisted in 35 biopsy confirmed CD children aged between two and 18 years.The control lot included 40 children with normal duodenal morphology on intestinal biopsy that underwent upper digestive endoscopy for different gastrointestinal symptoms.Serum samples were provided from all subjects for IgA measurement, IgA anti tTG and EMA assessment. Immulite 2500 Anti tTG IgA (Siemens Co, LA, USA) and ImmuLisa anti-hu tTG antibody IgA ELISA (Immco Diagnostics Inc, NY, USA) kits were used for tTG-Ab assessment. All children underwent HLA typing for DQ2/DQ8. The sensitivity for IgA tTG assessment was greater for chemiluminescence (93,3%) versus ELISA (86,6%), p[0,05, while specificity, positive and negative predictive value didn�t register significant differences. Statistical comparison of the two tested methods revealed a better sensitivity for chemiluminescence. Diagnosis algorithm optimisation may be obtained by associating IgA anti tTG-Ab assessment using chemiluminescence followed by EMA confirmation by indirect immunofluorescence for CD screening.

show abstract

“…TG2-targeted antibodies may be produced also in other autoimmune or inflammatory conditions, including inflammatory bowel diseases, but epitope and IgG subclass usage differs from celiac disease [ 139 ] and clinical implication of these antibodies is uncertain. In addition, in a mouse colitis model TG2 was reported to be required for survival [ 140 ].…”

Section: Transglutaminase 2 In Celiac Disease and Other Gastroenterolmentioning

confidence: 99%

Transglutaminase 2 in human diseases

Szondy¹,

Korponay-Szabó²,

Király³

et al. 2017

BioMedicine

View full text Add to dashboard Cite

Transglutaminase 2 (TG2) is an inducible transamidating acyltransferase that catalyzes Ca(2+)-dependent protein modifications. In addition to being an enzyme, TG2 also serves as a G protein for several seven transmembrane receptors and acts as a co-receptor for integrin β1 and β3 integrins distinguishing it from other members of the transglutaminase family. TG2 is ubiquitously expressed in almost all cell types and all cell compartments, and is also present on the cell surface and gets secreted to the extracellular matrix via non-classical mechanisms. TG2 has been associated with various human diseases including inflammation, cancer, fibrosis, cardiovascular disease, neurodegenerative diseases, celiac disease in which it plays either a protective role, or contributes to the pathogenesis. Thus modulating the biological activities of TG2 in these diseases will have a therapeutic value.

show abstract

IgG anti-tTG responses in different autoimmune conditions differ in their epitope targets and subclass usage

Cited by 10 publications

References 68 publications

IgA and IgG Antitransglutaminase 2 Antibodies in the Diagnosis of Celiac Disease

IgA and IgG Antitransglutaminase 2 Antibodies in the Diagnosis of Celiac Disease

Chemiluminescent Immunoassay versus Enzyme Linked Immunosorbent Assays for IgA Anti-Tissue Transglutaminase Antibodies Assessment in Celiac Disease Children

Transglutaminase 2 in human diseases

Contact Info

Product

Resources

About